A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)
- Conditions
- Rheumatoid Arthritis
- Interventions
- Registration Number
- NCT02706951
- Lead Sponsor
- AbbVie
- Brief Summary
The study objective of Period 1 of this study is to compare the safety and efficacy (signs and symptoms) of upadacitinib 30 mg once daily (QD) alone and upadacitinib 15 mg QD alone versus continuing MTX alone adults with moderately to severely active rheumatoid arthritis (RA) with an inadequate response to MTX.
The study objective of Period 2 is to evaluate the long term safety, tolerability, and efficacy of upadacitinib 30 mg QD and 15 mg QD in adults with RA who had completed Period 1.
- Detailed Description
The study includes a 35-day screening period; a 14-week randomized, double-blind, parallel-group, controlled treatment period (Period 1); a 246-week blinded extension period (Period 2); and a 30-day follow-up visit.
Participants who met eligibility criteria were to be randomized in a 2:2:1:1 ratio to one of four treatment groups:
* Group 1: upadacitinib 30 mg QD (Period 1) → upadacitinib 30 mg QD (Period 2)
* Group 2: upadacitinib 15 mg QD (Period 1) → upadacitinib 15 mg QD (Period 2)
* Group 3: MTX (Period 1) → upadacitinib 30 mg QD (Period 2)
* Group 4: MTX (Period 1) → upadacitinib 15 mg QD (Period 2)
Starting with implementation of Protocol Amendment 5, all participants in the extension period will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 648
- Diagnosis of RA for >= 3 months.
- Subjects must have been on oral or parenteral MTX therapy >= 3 months and on a stable dose for >= 4 weeks prior to first dose of study drug.
- Must have discontinued all conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) (other than MTX) >= 4 weeks prior to first dose of study drug.
- Meets the following minimum disease activity criteria: >= 6 swollen joints (based on 66 joint counts) and >= 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.
- Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).
- Prior exposure to any biological disease-modifying anti-rheumatic drugs (bDMARDs).
- Current diagnosis of inflammatory joint disease other than RA. Current diagnosis of secondary Sjogren's Syndrome is permitted.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Methotrexate / Upadacitinib 30 mg Placebo Methotrexate Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib once daily for 14 weeks. Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260. Methotrexate / Upadacitinib 15 mg Placebo Upadacitinib Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib for 14 weeks. Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260. Methotrexate / Upadacitinib 30 mg Placebo Upadacitinib Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib once daily for 14 weeks. Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260. Upadacitinib 30 mg Placebo Methotrexate Period 1: Participants receive upadacitnib 30 mg once daily and placebo to methotrexate once weekly for 14 weeks. Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260. Upadacitinib 15 mg Placebo Methotrexate Period 1: Participants receive upadacitnib 15 mg once daily and placebo to methotrexate once weekly for 14 weeks. Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260. Methotrexate / Upadacitinib 15 mg Placebo Methotrexate Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib for 14 weeks. Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260. Upadacitinib 30 mg Upadacitinib Period 1: Participants receive upadacitnib 30 mg once daily and placebo to methotrexate once weekly for 14 weeks. Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260. Upadacitinib 15 mg Upadacitinib Period 1: Participants receive upadacitnib 15 mg once daily and placebo to methotrexate once weekly for 14 weeks. Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260. Methotrexate / Upadacitinib 30 mg Methotrexate Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib once daily for 14 weeks. Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260. Methotrexate / Upadacitinib 30 mg Upadacitinib Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib once daily for 14 weeks. Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260. Methotrexate / Upadacitinib 15 mg Methotrexate Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib for 14 weeks. Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260. Methotrexate / Upadacitinib 15 mg Upadacitinib Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib for 14 weeks. Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260.
- Primary Outcome Measures
Name Time Method Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14 Baseline and week 14 The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 14. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
1. ≥ 20% improvement in 68-tender joint count;
2. ≥ 20% improvement in 66-swollen joint count; and
3. ≥ 20% improvement in at least 3 of the 5 following parameters:
* Physician global assessment of disease activity
* Patient global assessment of disease activity
* Patient assessment of pain
* Health Assessment Questionnaire - Disability Index (HAQ-DI)
* High-sensitivity C-reactive protein (hsCRP).Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 14 Week 14 The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 14.
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
A DAS28 score less than or equal to 3.2 indicates low disease activity.
- Secondary Outcome Measures
Name Time Method Change From Baseline in in Disease Activity Score 28 (CRP) at Week 14 Baseline to week 14 The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline in DAS28 (CRP) indicates improvement in disease activity.
Change From Baseline in Heath Assessment Questionnaire and Disability Index (HAQ-DI) at Week 14 Baseline to week 14 The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 14 Baseline to week 14 The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).
The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 14 Week 14 The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
A DAS28 score less than 2.6 indicates clinical remission.Change From Baseline in Duration of Morning Stiffness at Week 14 Baseline to week 14 Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days. A negative change from Baseline indicates improvement.
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 14 Baseline and week 14 Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:
1. ≥ 50% improvement in 68-tender joint count;
2. ≥ 50% improvement in 66-swollen joint count; and
3. ≥ 50% improvement in at least 3 of the 5 following parameters:
* Physician global assessment of disease activity
* Patient global assessment of disease activity
* Patient assessment of pain
* Health Assessment Questionnaire - Disability Index (HAQ-DI)
* High-sensitivity C-reactive protein (hsCRP).Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 14 Baseline and week 14 Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:
1. ≥ 70% improvement in 68-tender joint count;
2. ≥ 70% improvement in 66-swollen joint count; and
3. ≥ 70% improvement in at least 3 of the 5 following parameters:
* Physician global assessment of disease activity
* Patient global assessment of disease activity
* Patient assessment of pain
* Health Assessment Questionnaire - Disability Index (HAQ-DI)
* High-sensitivity C-reactive protein (hsCRP).
Trial Locations
- Locations (153)
W. Broward Rheum Assoc Inc. /ID# 146010
🇺🇸Tamarac, Florida, United States
Sarasota Arthritis Center /ID# 146011
🇺🇸Sarasota, Florida, United States
University of Arizona Cancer Center - North Campus /ID# 147175
🇺🇸Tucson, Arizona, United States
Vanguard Medical Research, LLC /ID# 153124
🇺🇸Shreveport, Louisiana, United States
Albuquerque Clinical Trials, Inc /ID# 147618
🇺🇸Albuquerque, New Mexico, United States
STAT Research, Inc. /ID# 143770
🇺🇸Vandalia, Ohio, United States
Sheba Medical Center /ID# 144824
🇮🇱Ramat Gan, Israel
NHO Kyushu Medical Center /ID# 148280
🇯🇵Fukuoka-shi, Fukuoka, Japan
Centro de Enfermedades /ID# 153543
🇦🇷Santa Fe, Argentina
Coastal Carolina Health Care /ID# 149275
🇺🇸New Bern, North Carolina, United States
Trinity Universal Res Assoc /ID# 150138
🇺🇸Carrollton, Texas, United States
Diagnostic Group Integrated He /ID# 148725
🇺🇸Beaumont, Texas, United States
P&I Clinical Research /ID# 151358
🇺🇸Lufkin, Texas, United States
SW Rheumatology Res. LLC /ID# 147620
🇺🇸Mesquite, Texas, United States
Mansfield Health Center /ID# 161627
🇺🇸Mansfield, Massachusetts, United States
Consultorio Reumatologic Pampa /ID# 145979
🇦🇷Buenos Aires, Argentina
Arthritis and Osteo Assoc /ID# 147177
🇺🇸Las Cruces, New Mexico, United States
Arthritis Clinic of Central TX /ID# 149266
🇺🇸San Marcos, Texas, United States
Aurora Rheumatology and Immunotherapy Center /ID# 160811
🇺🇸Franklin, Wisconsin, United States
Centro de Educación Médica e Investigaciones Clínicas "Norberto Quimo" - CEMIC /ID# 149176
🇦🇷Buenos Aires, Argentina
Healthcare Research Consultant /ID# 147632
🇺🇸Tulsa, Oklahoma, United States
Mautalen Salud e Investigacion /ID# 145980
🇦🇷Buenos Aires, Argentina
CTCenter MaVe, s.r.o. /ID# 144823
🇨🇿Olomouc, Olomoucky Kraj, Czechia
Barzilai Medical Center /ID# 144744
🇮🇱Ashkelon, Israel
Royal Prince Alfred Hospital /ID# 146028
🇦🇺Camperdown, New South Wales, Australia
Bnai Zion Medical Center /ID# 144745
🇮🇱Haifa, Israel
Thomayerova nemocnice /ID# 144736
🇨🇿Prague 4, Praha 4, Czechia
DM Clinical Research /ID# 151359
🇺🇸Tomball, Texas, United States
Aso Iizuka Hospital /ID# 148272
🇯🇵Iizuka-shi, Fukuoka, Japan
Nuselská poliklinika, Revmatologie /ID# 145986
🇨🇿Prague 4, Praha 4, Czechia
Inoue Hospital /ID# 148069
🇯🇵Takasaki, Gunma, Japan
NHO Kyushu Medical Center /ID# 148279
🇯🇵Fukuoka-shi, Fukuoka, Japan
Bay Side Misato Medical Center /ID# 148281
🇯🇵Kochi-shi, Kochi, Japan
Seirei Hamamatsu General Hosp /ID# 148270
🇯🇵Hamamatsu, Japan
Sasebo Chuo Hospital /ID# 148275
🇯🇵Sasebo-city, Nagasaki, Japan
Osaka Red Cross Hospital /ID# 148267
🇯🇵Osaka-shi, Osaka, Japan
Dr. Ramon L. Ortega-Colon, MD /ID# 145989
🇵🇷Carolina, Puerto Rico
Miyasato Clinic /ID# 148271
🇯🇵Shunan, Japan
Wits Clinical Research Site /ID# 149835
🇿🇦Johannesburg, Gauteng, South Africa
Hospital Univ Germans Trias I /ID# 146037
🇪🇸Barcelona, Spain
Ponce School of Medicine /ID# 145990
🇵🇷Ponce, Puerto Rico
Matsuta Clinic /ID# 148278
🇯🇵Tokyo, Japan
National Hospital Organization Shimoshizu National Hospital /ID# 148273
🇯🇵Yotsukaido, Japan
Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 146002
🇺🇦Vinnytsia, Vinnytska Oblast, Ukraine
Regional Clinical Hospital /ID# 152007
🇺🇦Ivano-frankivsk, Ukraine
Hospital Infanta Luisa /ID# 144771
🇪🇸Sevilla, Spain
Hospital Plató /ID# 145999
🇪🇸Barcelona, Spain
Zaporizhzhia Regional Clinical /ID# 146000
🇺🇦Zaporizhia, Ukraine
Hospital Universitario La Fe /ID# 158013
🇪🇸Valencia, Spain
Great Lakes Clinical Trials /ID# 150935
🇺🇸Chicago, Illinois, United States
Accurate Clinical Management /ID# 143768
🇺🇸Houston, Texas, United States
Accurate Clinical Research /ID# 143769
🇺🇸Houston, Texas, United States
Pioneer Research Solutions, Inc. /ID# 143765
🇺🇸Houston, Texas, United States
PRN Professional Research Network of Kansas, LLC /ID# 143761
🇺🇸Wichita, Kansas, United States
Reg. Clinical Hosptial Concepcion /ID# 151267
🇨🇱Concepcion, Chile
Quantum Research Stgo. /ID# 145983
🇨🇱Santiago, Chile
ReumaClinic Genk /ID# 146030
🇧🇪Genk, Belgium
Diag Consult Ctr 17 Sofia EOOD /ID# 144730
🇧🇬Sofia, Bulgaria
Vital Medical Center Orvosi es /ID# 144740
🇭🇺Veszprém, Veszprem, Hungary
Fejer Megyei Szent Gyorgy Korh /ID# 144741
🇭🇺Szekesfehervar, Hungary
MediTrials /ID# 159745
🇪🇪Tartu, Tartumaa, Estonia
Pest Megyei Flor Ferenc Korhaz /ID# 144742
🇭🇺Kistarcsa, Hungary
Algemeen Stedelijk Ziekenhuis /ID# 148720
🇧🇪Aalst, Oost-Vlaanderen, Belgium
North Estonian Medical Centre /ID# 145455
🇪🇪Tallinn, Estonia
Cryptex Investigación Clínica S.A de C.V /ID# 147095
🇲🇽Mexico City, Mexico
Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 149521
🇵🇱Warszawa, Mazowieckie, Poland
Clinical Hospital No.1 n.a. N.I.Pirogov /ID# 147255
🇷🇺Moscow, Moskva, Russian Federation
Republican Clin Hos n.a. Baran /ID# 147251
🇷🇺Petrozavodsk, Russian Federation
Institute for Rheumatology /ID# 144762
🇷🇸Belgrade, Beograd, Serbia
NSC-Strazhesko Ist Cardiology /ID# 152004
🇺🇦Kiev, Ukraine
Universita di Catanzaro Magna Graecia /ID# 144747
🇮🇹Catanzaro, Calabria, Italy
General Hospital of Athens "Ippokratio" /ID# 144739
🇬🇷Athens, Greece
Samara Regional Clinical Hosp /ID# 150934
🇷🇺Samara, Russian Federation
Institute for Rheumatology /ID# 144759
🇷🇸Belgrade, Beograd, Serbia
Instituto Portugues De Reumatologia /ID# 149281
🇵🇹Lisbon, Lisboa, Portugal
Сity Clinical Hospital 4 /ID# 145994
🇷🇺Ivanovo, Russian Federation
Centro Hospitalar De Vila Nova /ID# 146036
🇵🇹Vila Nova De Gaia, Porto, Portugal
City Clinical Hospital Botkina /ID# 145995
🇷🇺Moscow, Russian Federation
Medyczne Centrum Hetmanska /ID# 144751
🇵🇱Poznań, Wielkopolskie, Poland
Centro Hospitalar Lisboa Norte, EPE /ID# 146035
🇵🇹Lisboa, Portugal
Spitalul Municipal Ploiesti /ID# 144756
🇷🇴Ploiesti, Romania
Institute for Rheumatology /ID# 144761
🇷🇸Belgrade, Beograd, Serbia
WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 157622
🇵🇱Wrocław, Dolnoslaskie, Poland
Centro Hospitalar Baixo Vouga /ID# 152916
🇵🇹Porto, Portugal
Orenburg State Medical Academy /ID# 145992
🇷🇺Orenburg, Russian Federation
Tiervlei Trial Centre /ID# 153086
🇿🇦Cape Town, Western Cape, South Africa
Elite Clinical Studies, LLC /ID# 143760
🇺🇸Phoenix, Arizona, United States
Quality Clinical Research Inc. /ID# 156415
🇺🇸Omaha, Nebraska, United States
Health Research Oklahoma /ID# 159550
🇺🇸Oklahoma City, Oklahoma, United States
Nashville Arthritis and Rheumatology /ID# 162641
🇺🇸Nashville, Tennessee, United States
Alabama Medical Group, PC /ID# 153941
🇺🇸Mobile, Alabama, United States
Cordis S.A. /Id# 152621
🇦🇷Salta, Argentina
Rheum Assoc of North Alabama /ID# 146009
🇺🇸Huntsville, Alabama, United States
ArthroCare Arthritis Care & Re /ID# 143751
🇺🇸Gilbert, Arizona, United States
NEA Baptist Womens Clinic /ID# 148904
🇺🇸Jonesboro, Arkansas, United States
C.V. Mehta MD, Med Corporation /ID# 143762
🇺🇸Hemet, California, United States
South Florida Research Ph I-IV /ID# 151983
🇺🇸Miami Springs, Florida, United States
Arthritis Assoc & Osteo Ctr /ID# 147176
🇺🇸Colorado Springs, Colorado, United States
Advent Clinical Research /ID# 143767
🇺🇸Pinellas Park, Florida, United States
Ochsner Clinic Foundation /ID# 153573
🇺🇸Baton Rouge, Louisiana, United States
The Arthritis & Diabetes Clinic, Inc. /ID# 160809
🇺🇸Monroe, Louisiana, United States
Dartmouth-Hitchcock Medical Center /ID# 146008
🇺🇸Lebanon, New Hampshire, United States
Innovative Clinical Research /ID# 143757
🇺🇸Greenville, South Carolina, United States
Arth and Osteo Clin Brazo Valley /ID# 160810
🇺🇸College Station, Texas, United States
Adriana Pop-Moody MD Clinic PA /ID# 147627
🇺🇸Corpus Christi, Texas, United States
Sun Research Institute /ID# 159553
🇺🇸San Antonio, Texas, United States
Adv Rheumatology of Houston /ID# 162609
🇺🇸The Woodlands, Texas, United States
Arthritis & Osteoporosis Clinic /ID# 143752
🇺🇸Waco, Texas, United States
Ctr for Arth and Rheum Disease /ID# 143759
🇺🇸Chesapeake, Virginia, United States
Ctr Privado Med Familiar /ID# 149183
🇦🇷Buenos Aires, Argentina
Quantum Research LTDA. /ID# 145984
🇨🇱Puerto Varas, Chile
Rheuma-Zentrum Wien-Oberlaa /ID# 144728
🇦🇹Wien, Austria
UMHAT Sv. Ivan Rilski /ID# 147351
🇧🇬Sofia, Bulgaria
Medical Plus, s.r.o. /ID# 144821
🇨🇿Uherské Hradište, Czechia
RHEUMA s.r.o. /ID# 144737
🇨🇿Breclav, Czechia
Magyar Honvedseg Egeszsegugyi Kozpont /ID# 144743
🇭🇺Budapest, Hungary
The Lady Davis Carmel MC /ID# 147174
🇮🇱Haifa, Israel
A.O.U.I. di Verona Policlinico /ID# 144746
🇮🇹Verona, Italy
Kondo Clinic for Rheum & Ortho /ID# 148268
🇯🇵Fukuoka-shi, Fukuoka, Japan
Nagasaki University Hospital /ID# 149859
🇯🇵Nagasaki-shi, Nagasaki, Japan
Center for Arthritis and Clinical Rheumatology Matsubara Clinic /ID# 148269
🇯🇵Kumamoto-shi, Kumamoto, Japan
Kumamoto Shinto General Hospital /ID# 148286
🇯🇵Kumamoto-shi, Kumamoto, Japan
Ohira Orthopaedic Hospital /ID# 157944
🇯🇵Hyuga, Japan
Shirahama Hamayu Hospital /ID# 148277
🇯🇵Nishimura, Japan
Sanuki Municipal Hospital /ID# 158080
🇯🇵Sanuki, Japan
Hokkaido University Hospital /ID# 148285
🇯🇵Sapporo, Japan
Hokkaido Medical Center for Rheumatic Diseases /ID# 148274
🇯🇵Sapporo, Japan
Takaoka Rheumatic Orthopedic Clinic /ID# 148068
🇯🇵Takaoka, Japan
Desarrollos Biomedicos y Biotc /ID# 147379
🇲🇽Monterrey, Nuevo LEON, Mexico
REUMED Sp.z o.o. Filia nr 1 /ID# 144752
🇵🇱Lublin, Lubelskie, Poland
Osteo-Medic spolka cywilna /ID# 144753
🇵🇱Białystok, Podlaskie, Poland
Centrum Badań Klinicznych Pi-House /ID# 149520
🇵🇱Gdansk, Pomorskie, Poland
NZOZ Centrum Reumatologiczne /ID# 144749
🇵🇱Elblag, Warminsko-mazurskie, Poland
LLC Medical Center /ID# 144758
🇷🇺Novosibirsk, Novosibirskaya Oblast, Russian Federation
Perm Clinical Center of FMBA /ID# 145993
🇷🇺Perm, Permskiy Kray, Russian Federation
Tver Regional Clinical Hosp. /ID# 147254
🇷🇺Tver, Tverskaya Oblast, Russian Federation
City Clinical Hospital #5 /ID# 149832
🇷🇺Nizhnij Novgorod, Russian Federation
Reg Clin Hosp n.a. Kuvatova G. /ID# 144757
🇷🇺UFA, Russian Federation
Yaroslavi State Medical Univer /ID# 147253
🇷🇺Yaroslavl, Russian Federation
Special Hospital for Rheuma /ID# 144760
🇷🇸Novi Sad, Vojvodina, Serbia
University of Pretoria /ID# 148740
🇿🇦Pretoria, Gauteng, South Africa
Synexus Helderberg Clinical Tr /ID# 148724
🇿🇦Cape Town, Western Cape, South Africa
Uludağ Üniversitesi Atatürk Rehabilitasyon Uygulama ve Araştırma Merkezi /ID# 144772
🇹🇷Osmangazi, Bursa, Turkey
Hospital Universitario de Valm /ID# 144770
🇪🇸Sevilla, Spain
Lviv Regional Clinical Hospita /ID# 154448
🇺🇦Lviv, Lvivska Oblast, Ukraine
Ctr Rheum, Immuno, Arthritis /ID# 143766
🇺🇸Fort Lauderdale, Florida, United States
Jefrey D. Lieberman, MD, P.C. /ID# 151816
🇺🇸Decatur, Georgia, United States
SW FL Clin Res Ctr, Tampa, FL /ID# 143763
🇺🇸Tampa, Florida, United States
University of South Florida /ID# 146004
🇺🇸Tampa, Florida, United States
BayCare Medical Group, Inc. /ID# 151985
🇺🇸Tampa, Florida, United States
BayCare Medical Group, Inc. /ID# 163595
🇺🇸Tampa, Florida, United States
Clinical Research West FL /ID# 148726
🇺🇸Tampa, Florida, United States
Tekton Research, Inc. /ID# 159554
🇺🇸Austin, Texas, United States